Intra-aortic balloon pumping in coronary artery disease
Related Experiment Videos
Insights
Intra-aortic balloon pumping effectively treats cardiogenic shock after myocardial infarction and relieves refractory angina. This intervention improves patient survival and reduces ischemic pain, offering a vital support in critical cardiac conditions.
Area of Science:
- Cardiology
- Cardiovascular Surgery
Background:
- Intra-aortic balloon pumping (IABP) is a mechanical circulatory support device.
- Indications for IABP include cardiogenic shock, severe left ventricular failure post-myocardial infarction, and refractory angina pectoris.
Purpose of the Study:
- To evaluate the efficacy of IABP in patients with cardiogenic shock and refractory angina.
- To assess the impact of IABP on survival rates and pain relief in specific cardiac conditions.
Main Methods:
- Retrospective analysis of 76 patients treated for cardiogenic shock and 42 patients for refractory angina.
- Data collection on weaning success, mortality, myocardial infarction rates, and pain relief.
Main Results:
- In cardiogenic shock: 55% weaned, 12% died within 3 months, 43% survived over 3 months.
- In refractory angina: 98% experienced prompt pain relief, 7% total mortality, 8% perioperative myocardial infarction.
- IABP provided prompt pain relief in 88% of suspected slowly evolving infarction cases.
Conclusions:
- Intra-aortic balloon pumping significantly improves prognosis in cardiogenic shock post-myocardial infarction.
- IABP effectively abolishes refractory ischemic pain, enhancing patient outcomes.
Abstract:
Cardiogenic shock and severe left ventricular failure after acute myocardial infarction, refractory angina pectoris at rest either of new onset or superimposed on stable angina pectoris, or occurring in the post infarct (less than 2 weeks) period, and the suspicion of a slowly evolving infarction are the main indications for intra-aortic balloon pumping at the Thoraxcenter. 76 patients were treated with intra-aortic balloon pumping for cardiogenic shock after acute myocardial infarction and left ventricular failure, 42/76 (55%) could be weaned, 9 (12%) died within 3 months, 33 (43%) survived over 3 months, to date 29 are alive. 42 patients with refractory angina at rest were treated with intra-aortic balloon pumping. Pain relief was prompt in 41 (98%), who subsequently underwent coronary artery bypass grafting. Total myocardial infarction rate was 11% (5/42), total mortality rate was 7%. Perioperative myocardial infarction rate was 8% (4/42) and perioperative mortality was 7% (3/42). Pain relief was prompt in 14/17 patients (82%) with post infarct refractory angina. In 3 patients pain persisted despite intra-aortic balloon pumping, all sustained a myocardial infarction, 1 died, 2 other patients were excluded for surgery. 12 patients underwent coronary artery bypass grafting, none died, none developed acute myocardial infarction, 3 have mild stable angina. In 8 patients a slowly evolving myocardial infarction was suspected. Pain relief was prompt in 7/8 (88%) after institution of intra-aortic balloon pumping. Intra-aortic balloon pumping improves prognosis in cardiogenic shock after myocardial infarction, and abolishes refractory ischemic pain.